New stock news | Strong performance in the dark market! (02659) is about to land on Hong Kong Stock Exchange, focusing on large-cap subcutaneous administration, self-immune and other fields.

On December 9th, (02659) had a strong performance in pre-market trading. As of the time of reporting, the dark trading of Levermore Securities showed a price of 54 Hong Kong dollars, a 104.7% increase from the IPO price of 26.38 Hong Kong dollars, with each lot of 100 shares, no commission included, earning 2762 Hong Kong dollars per lot. Pharma Company Boji Pharmaceuticals will be listed on December 10th, with CITIC SEC and Guotai Haitong as joint sponsors. According to public information, Boji Pharmaceuticals plans to issue 37.917 million H shares, with 90% for international sales and 10% for Hong Kong public sales. The issue price is set at 26.38 Hong Kong dollars per share, with an entrance fee of approximately 2664.60 Hong Kong dollars per lot. This IPO has attracted a strong lineup of cornerstone investors. According to the company's announcement, a total of 3 well-known investment institutions participated in the cornerstone investment, including Anhui Anke Biotechnology Hong Kong, DC Alpha SPC, Guotai Junan Securities Investment (related to OTC swaps) and other top institutions. The cornerstone investors subscribed a total of 200.6 million Hong Kong dollars, accounting for approximately 20.06% of the total funds raised. The active participation of long-term capital fully demonstrates confidence in the company's future development. Established in 2019 and headquartered in Shanghai, China, Boji Pharmaceuticals is a biotechnology company in the clinical and commercialization stage, utilizing advanced bio-manufacturing based on synthetic biology to develop and provide recombinant biopharmaceuticals in China, focusing on treating target diseases with limited drug options and complex manufacturing processes. The company's pipeline mainly includes 12 independently developed investigational products, including three core products (KJ017, KJ103, and SJ02 (Shengnuo)), four other clinical stage candidate drugs (BJ007, KJ015, SJ04, and KJ101), and five preclinical assets (BJ008, BJ009, BJ045, BJ047, and BJ044). Boji Pharmaceuticals' core products and other key assets are based on four core therapeutic areas, each with a wide range of treatment applications: - Large Volume Subcutaneous Administration - Introduction of KJ017 (recombinant human hyaluronidase) as a single drug and combination therapy, where the single drug is used as an alternative to intravenous infusion for large volume subcutaneous administration of crystalloid solutions, treating fluid loss for various reasons and assisting subcutaneous fluid replacement; can also be used in combination with therapeutic antibodies, converting existing intravenous formulations to subcutaneous formulations, reducing patient administration time from hours to minutes. - Antibody-Mediated Autoimmune Diseases - Independently developed KJ103 (an innovative IgG-degrading enzyme). This is the world's first and only low pre-existing antibody immunoglobulin G (IgG) degrading enzyme to reach Phase III clinical trials. - Assisted Reproductive Drugs - Developing a series of innovative products aimed at addressing key limitations of existing therapies in the field of assisted reproduction, including SJ02 and SJ04. According to Frost Sullivan's data, SJ02 is China's first approved long-acting recombinant follicle-stimulating hormone (FSH) product. - Recombinant Biological Products as Transformative Alternatives to Traditional Biochemical Products - Utilizing advanced bio-manufacturing based on synthetic biology to develop innovative recombinant biological products, replacing traditional biochemical extraction. According to Frost Sullivan's data, by 2033, Boji Pharmaceuticals' four strategic therapeutic areas' total clinical addressable market size in China is estimated to be approximately RMB 50 billion, including: (i) Large Volume Subcutaneous Administration, with recombinant hyaluronidase accounting for nearly RMB 7 billion, (ii) Antibody-Mediated Autoimmune Diseases, driven by the market size of IgG-related autoimmune diseases reaching RMB 26.7 billion, (iii) Assisted Reproduction reaching RMB 14.9 billion; and (iv) Recombinant Biopharmaceuticals exceeding RMB 5.3 billion, including ustekinumab and mucothiolysin. In terms of production capacity, Boji Pharmaceuticals has built a GMP-compliant production base in Shanghai, covering an area of approximately 63,000 square meters. The existing production base is equipped with production lines specifically designed for the production of complex biological products, with professional capabilities in producing recombinant protein drugs. With its innovative product pipeline in the four major therapeutic areas, strong R&D capabilities, and advanced production capacity, Boji Pharmaceuticals has demonstrated tremendous growth potential. With the dual drivers of ample funding and clear strategy upon officially entering the capital market, Boji Pharmaceuticals is expected to accelerate the commercialization process of its core products and translate technical advantages into solid performance growth.